CoMFA and docking study of novel estrogen receptor subtype selective ligands
暂无分享,去创建一个
[1] J A Katzenellenbogen,et al. Furans with basic side chains: synthesis and biological evaluation of a novel series of antagonists with selectivity for the estrogen receptor alpha. , 2001, Bioorganic & medicinal chemistry letters.
[2] Wolfgang Sippl,et al. Binding affinity prediction of novel estrogen receptor ligands using receptor-based 3-D QSAR methods. , 2002, Bioorganic & medicinal chemistry.
[3] G. Chang,et al. Macromodel—an integrated software system for modeling organic and bioorganic molecules using molecular mechanics , 1990 .
[4] C. Hansch,et al. Comparative QSAR analysis of estrogen receptor ligands. , 1999, Chemical reviews.
[5] M. Vieth,et al. DoMCoSAR: a novel approach for establishing the docking mode that is consistent with the structure-activity relationship. Application to HIV-1 protease inhibitors and VEGF receptor tyrosine kinase inhibitors. , 2000, Journal of medicinal chemistry.
[6] P Willett,et al. Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.
[7] K E Carlson,et al. Estrogen receptor subtype-selective ligands: asymmetric synthesis and biological evaluation of cis- and trans-5,11-dialkyl- 5,6,11, 12-tetrahydrochrysenes. , 1999, Journal of medicinal chemistry.
[8] R. Zauhar,et al. Computational studies on HIV-1 protease inhibitors: influence of calculated inhibitor-enzyme binding affinities on the statistical quality of 3D-QSAR CoMFA models. , 2000, Journal of medicinal chemistry.
[9] Anil K. Jaiswal,et al. Transcriptional Regulation of the Human Quinone Reductase Gene by Antiestrogen-liganded Estrogen Receptor-α and Estrogen Receptor-β* , 1998, The Journal of Biological Chemistry.
[10] W. C. Still,et al. The GB/SA Continuum Model for Solvation. A Fast Analytical Method for the Calculation of Approximate Born Radii , 1997 .
[11] R. Wade,et al. Prediction of drug binding affinities by comparative binding energy analysis , 1995 .
[12] S. Fawell,et al. Characterization and colocalization of steroid binding and dimerization activities in the mouse estrogen receptor , 1990, Cell.
[13] M Pastor,et al. Comparative binding energy analysis of HIV-1 protease inhibitors: incorporation of solvent effects and validation as a powerful tool in receptor-based drug design. , 1998, Journal of medicinal chemistry.
[14] T. Halgren,et al. A priori prediction of activity for HIV-1 protease inhibitors employing energy minimization in the active site. , 1995, Journal of medicinal chemistry.
[15] K. Chae,et al. Three-dimensional quantitative structure-activity relationship study of nonsteroidal estrogen receptor ligands using the comparative molecular field analysis/cross-validated r2-guided region selection approach. , 1998, Journal of medicinal chemistry.
[16] K. Grandien,et al. Printed in U.S.A. Copyright © 1997 by The Endocrine Society Comparison of the Ligand Binding Specificity and Transcript Tissue Distribution of Estrogen Receptors � and � , 2022 .
[17] B. Katzenellenbogen,et al. Pyrazole ligands: structure-affinity/activity relationships and estrogen receptor-alpha-selective agonists. , 2000, Journal of medicinal chemistry.
[18] A. Hopfinger. A QSAR investigation of dihydrofolate reductase inhibition by Baker triazines based upon molecular shape analysis , 1980 .
[19] Roger Perkins,et al. QSAR Models for Binding of Estrogenic Compounds to Estrogen Receptor α and β Subtypes. , 1997, Endocrinology.
[20] Massimo Bertelli,et al. Selective inhibition of 6-phosphogluconate dehydrogenase from Trypanosoma brucei , 2001, J. Comput. Aided Mol. Des..
[21] S. Pickett,et al. GRid-INdependent descriptors (GRIND): a novel class of alignment-independent three-dimensional molecular descriptors. , 2000, Journal of medicinal chemistry.
[22] D. Rognan,et al. Protein-based virtual screening of chemical databases. 1. Evaluation of different docking/scoring combinations. , 2000, Journal of medicinal chemistry.
[23] R. Cramer,et al. Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. , 1988, Journal of the American Chemical Society.
[24] J. Polman,et al. ERβ: Identification and characterization of a novel human estrogen receptor , 1996 .
[25] M. Murcko,et al. Consensus scoring: A method for obtaining improved hit rates from docking databases of three-dimensional structures into proteins. , 1999, Journal of medicinal chemistry.
[26] R. Clark,et al. Consensus scoring for ligand/protein interactions. , 2002, Journal of molecular graphics & modelling.
[27] Paul Labute,et al. Binary Quantitative Structure-Activity Relationship (QSAR) Analysis of Estrogen Receptor Ligands , 1999, J. Chem. Inf. Comput. Sci..
[28] M. Adams,et al. Coronary artery and cultured aortic smooth muscle cells express mRNA for both the classical estrogen receptor and the newly described estrogen receptor beta , 1998, The Journal of Steroid Biochemistry and Molecular Biology.
[29] R. Glen,et al. Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation. , 1995, Journal of molecular biology.
[30] Ferran Sanz,et al. 3D-QSAR methods on the basis of ligand–receptor complexes. Application of COMBINE and GRID/GOLPE methodologies to a series of CYP1A2 ligands , 2000, J. Comput. Aided Mol. Des..
[31] M Carlquist,et al. Structure of the ligand‐binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist , 1999, The EMBO journal.